Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Physical activity and joint health study of once-weekly efanesoctocog alfa in previously treated patients aged 12 years and older with severe haemophilia A
2022-500275-31-00Phase 3Completed
- Sponsor
- Sobi
- Start
- Jun 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 15
01
Overview
Phase 3, open-label, single-arm trial of efanesoctocog alfa in hemophilia A, sponsored by Sobi. Primary endpoint: Change from baseline in IPAQ scoring. Started Jun 2023; status: completed.
02
Drugs
efanesoctocog alfa
03
Conditions
hemophilia A
Beyond the preview
Go deeper on 2022-500275-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-500275-31-00.